CX Partners backed Research Player Veeda Clinical Research refiles DRHP for IPO
CX Partners backed Research Player, Veeda Clinical Research , is an independent, global full-service contract research organization (“CRO”) offering a comprehensive portfolio of services across various stages of the drug development value chain, has refiled its Draft Red Herring Prospectus (DRHP) with capital markets regulator, Securities and Exchange Board of India (SEBI) to raise funds through Initial Public Offering (IPO). The Company had earlier filed its IPO papers with Sebi on September 27, 2021. The IPO, with a face value of Rs 2, is a mix of fresh issue of shares up to Rs 185 crore and an offer-for-sale up to 13 million equity shares by Promoter and Other Selling Shareholders. Offer for Sale consists of shareholders selling shares up to 3,493,895 equity shares by Basil Private Limited, up to 7,359,620 equity shares by Bondway Investments Inc., up to 810,000 equity shares by Dr. S N Vinaya Babu, up to 690,210 equity shares by Sabre Partners AIF Trust, up to 198,795 equity s...